Short answer
Disc Medicine, Inc. (IRON) filed an 8-K current report with the SEC on July 30, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 results covered quarter ended June 30, 2026.
Disc Medicine, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 results covered quarter ended June 30, 2026
- Corporate update accompanied the financial results announcement
- Detailed financial figures and management commentary in Exhibit 99.1
Item EX-99.1 · Exhibit EX-99.1
- Q2 net loss $59.5M versus $55.2M; six-month loss widened to $123.0M versus $89.3M
- Cash, equivalents, and marketable securities $717.7M, funding operations into 2029 without near-term financing pressure
- Bitopertin APOLLO Phase 3 enrollment complete at 183 patients; topline data expected Q4 2026 and FDA decision by mid-2027
- Selcodebart RALLY-MF showed 56% major and 72% overall anemia response rates, supporting potential pivotal development
- DISC-3405 RESTORE-PV enrollment complete, with initial polycythemia vera data expected Q3 2026
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Disc Medicine, Inc. 8-K filings
Get the next IRON 8-K as it lands
Follow IRON for push alerts, or ask the research agent what this filing means.